mProX™ Human TNFRSF8 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF8, also known as CD30, has various applications in different fields. In the context of Alzheimer's disease (AD) and mild cognitive impairment (MCI), TNFRSF8 is studied as a potential biomarker for early detection. Urinary cytokine concentrations, including TNFRSF8, IL6ST, and IL-19, are analyzed to identify associations with AD and MCI development. Diagnostic models using these cytokines show promising performance in distinguishing AD from cognitively normal individuals. In-silico analysis enhances understanding of molecular mechanisms related to AD. TNFRSF8 is also explored in the context of cancer diagnosis and treatment. It is considered a tumor marker and is found on the surface of specific cells, including immune cells and cancer cells. CD30-targeted therapies are being investigated for CD30-positive lymphomas and autoimmune disorders. Additionally, TNFRSF8 is studied in triple-negative breast cancer (TNBC) to establish a cytokine-related gene signature for distinguishing and predicting prognosis. The signature includes TNFRSF8 along with other genes. Furthermore, TNFRSF8's role in adult T-cell leukemia/lymphoma (ATL) progression is examined. CD30 overexpression is observed in ATL cases caused by human T-cell leukemia virus type 1 (HTLV-1) infection, and its functions during disease progression are explored. Lastly, in the context of Mycobacterium tuberculosis (Mtb) infection, CD30 co-stimulation is found to drive the differentiation of protective T cells. CD30 expression on CD4 T cells is required for survival and protection against Mtb infection.